TW483757B - A pharmceutical formulation containing melatonin for use in treating preventing symptoms of dependence on, tolerance of, or addiction to benzodiazepine drugs - Google Patents

A pharmceutical formulation containing melatonin for use in treating preventing symptoms of dependence on, tolerance of, or addiction to benzodiazepine drugs Download PDF

Info

Publication number
TW483757B
TW483757B TW085104319A TW85104319A TW483757B TW 483757 B TW483757 B TW 483757B TW 085104319 A TW085104319 A TW 085104319A TW 85104319 A TW85104319 A TW 85104319A TW 483757 B TW483757 B TW 483757B
Authority
TW
Taiwan
Prior art keywords
melatonin
benzodiazepine
patients
treatment
pharmaceutical composition
Prior art date
Application number
TW085104319A
Other languages
English (en)
Chinese (zh)
Inventor
Nava Zisapel
Original Assignee
Neurim Pharma 1991
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/381,535 external-priority patent/US6469044B1/en
Application filed by Neurim Pharma 1991 filed Critical Neurim Pharma 1991
Application granted granted Critical
Publication of TW483757B publication Critical patent/TW483757B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Toxicology (AREA)
  • Anesthesiology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
TW085104319A 1995-02-01 1996-04-12 A pharmceutical formulation containing melatonin for use in treating preventing symptoms of dependence on, tolerance of, or addiction to benzodiazepine drugs TW483757B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/381,535 US6469044B1 (en) 1995-02-01 1995-02-01 Method for treating patients suffering from drug dependencies which lead to plasma melationin deficiencies
EP95303853A EP0724878B1 (en) 1995-02-01 1995-06-06 Use of melatonin for treating patients suffering from drug dependencies

Publications (1)

Publication Number Publication Date
TW483757B true TW483757B (en) 2002-04-21

Family

ID=26140195

Family Applications (1)

Application Number Title Priority Date Filing Date
TW085104319A TW483757B (en) 1995-02-01 1996-04-12 A pharmceutical formulation containing melatonin for use in treating preventing symptoms of dependence on, tolerance of, or addiction to benzodiazepine drugs

Country Status (22)

Country Link
JP (1) JP4516159B2 (da)
CN (1) CN1083263C (da)
AT (1) AT408188B (da)
AU (1) AU695366B2 (da)
BG (1) BG62876B1 (da)
BR (1) BR9607169A (da)
CZ (1) CZ291349B6 (da)
DK (1) DK176081B1 (da)
EE (1) EE03384B1 (da)
FI (1) FI119586B (da)
IS (1) IS1980B (da)
LU (1) LU90118B1 (da)
LV (1) LV11940B (da)
MD (1) MD1716C2 (da)
NO (1) NO312814B1 (da)
NZ (1) NZ298878A (da)
PL (1) PL183148B1 (da)
SI (1) SI9620022A (da)
SK (1) SK284521B6 (da)
TR (1) TR199700723T1 (da)
TW (1) TW483757B (da)
WO (1) WO1996023496A1 (da)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL150190A0 (en) 2000-01-05 2002-12-01 Neurim Pharma 1991 Method and formulation for treating resistance to antihypertensives and related conditions
IL149377A (en) * 2002-04-28 2012-10-31 Neurim Pharma 1991 Pharmaceutical formulation comprising melatonin for the potentiation of the effect of hypnotic compounds
IL155666A (en) 2003-04-29 2013-12-31 Neurim Pharma 1991 Insomnia treatment
US9119846B2 (en) 2003-04-29 2015-09-01 Neurim Pharmaceuticals (1991) Ltd. Method and composition for enhancing cognition in alzheimer's patients
IL330095A (en) 2012-01-26 2026-08-01 Vanda Pharmaceuticals Inc Tesimalta for use in the treatment of asynchronous circadian rhythm of cortisol
US11918557B2 (en) 2012-01-26 2024-03-05 Vanda Pharmaceuticals Inc. Treatment of circadian rhythm disorders
IL266159B2 (en) 2012-12-18 2024-07-01 Vanda Pharmaceuticals Inc Treatment of circadian rhythm disorders
US11090285B2 (en) 2013-11-12 2021-08-17 Vanda Pharmaceuticals Inc Treatment of circadian rhythm disorders
US10376487B2 (en) 2013-11-12 2019-08-13 Vanda Pharmaceuticals Inc. Method of treatment
DK3337462T3 (da) * 2016-10-31 2020-10-12 Neurim Pharma 1991 Melatonin-minitabletter og fremgangsmåde til fremstilling heraf

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69229490T2 (de) * 1991-05-09 2000-02-17 Neurim Pharmaceuticals (1991) Ltd., Tel Aviv Melatonin enthaltende Arzneimittel
IT1251544B (it) * 1991-05-13 1995-05-17 Gabriele Biella Composizioni farmaceutiche attive nella terapia dei disturbi del sonno comprendenti melatonina o un suo derivato in associazione con un derivato benzodiazepinico

Also Published As

Publication number Publication date
PL183148B1 (pl) 2002-05-31
CZ240597A3 (cs) 1998-01-14
BR9607169A (pt) 1997-11-11
MD1716C2 (ro) 2002-02-28
PL321630A1 (en) 1997-12-08
EE9700166A (et) 1998-02-16
ATA901396A (de) 2001-02-15
JP4516159B2 (ja) 2010-08-04
SK284521B6 (sk) 2005-05-05
FI973185A0 (fi) 1997-07-31
MD970254A (en) 1999-05-31
SI9620022A (sl) 1998-10-31
TR199700723T1 (xx) 1998-02-21
EE03384B1 (et) 2001-04-16
NZ298878A (en) 1999-05-28
IS1980B (is) 2005-01-14
DK89697A (da) 1997-07-30
MX9705856A (es) 1998-07-31
AU4457496A (en) 1996-08-21
FI119586B (fi) 2009-01-15
SK103097A3 (en) 1998-01-14
JPH10513177A (ja) 1998-12-15
CN1083263C (zh) 2002-04-24
BG101803A (en) 1998-04-30
NO973531L (no) 1997-09-30
WO1996023496A1 (en) 1996-08-08
CZ291349B6 (cs) 2003-02-12
CN1172431A (zh) 1998-02-04
LV11940A (lv) 1998-01-20
AT408188B (de) 2001-09-25
MD1716B2 (en) 2001-08-31
LV11940B (en) 1998-05-20
FI973185L (fi) 1997-09-30
DK176081B1 (da) 2006-04-18
AU695366B2 (en) 1998-08-13
IS4532A (is) 1997-07-25
NO973531D0 (no) 1997-07-31
NO312814B1 (no) 2002-07-08
BG62876B1 (bg) 2000-10-31
LU90118B1 (fr) 1997-11-13

Similar Documents

Publication Publication Date Title
KR100425045B1 (ko) 약물중독의치료를위한멜라토닌함유약학적조성물
KR101000624B1 (ko) 멜라토닌을 포함하는 약제학적 제제
EP1272177B1 (en) Method and formulation for treating resistance to antihypertensives and related conditions
US6344487B1 (en) Treatment of insomnia
CN1083263C (zh) 褪黑激素在治疗药物成瘾之患者中的应用
JPH10513177A5 (da)
Pagot et al. Comparison of the efficacy and tolerability of zolpidem 20 mg and triazolam 0.5 mg in anxious or depressed insomniac patients
CA2211839C (en) Use of melatonin for treating patients suffering from drug addiction
CN102274160B (zh) 用于治疗对抗高血压药的抗药性和相关病症的方法和制剂
HK1001218B (en) Use of melatonin for treating patients suffering from drug dependencies
MXPA97005856A (en) Use of melatonine in the manufacture of unmedicament to deal with addiction to dro

Legal Events

Date Code Title Description
GD4A Issue of patent certificate for granted invention patent
MK4A Expiration of patent term of an invention patent